Antibody peptide epitope conjugates for αPD-1 therapy-resistant head and neck squamous cell carcinoma
Shui, Y. I.; Millar, D. G.; Altenburger, L. M.; Chrisikos, T.; Kalbfleisch, M. J.; Hata, A.; Sadow, P. M.; Faquin, W. C.; Martinot, A. J.; Snyder, C. M.; Pittet, M. J.; Pai, S. I.; Cobbold, M.; Mempel, T. R.
Show abstract
Poor tumor antigenicity is an important cause of non-response to immune checkpoint blockade (ICB)-therapy in many cancer patients and mandates new treatment strategies. Here we explore the use of proteolytically activated antibody-peptide epitope conjugates (APECs) to redirect the immunological effector activities of tumor-infiltrating antiviral bystander CTLs against head and neck squamous cell carcinoma (HNSCC) by loading cancer cell surface MHC I proteins with viral peptides. We find that inflationary T cell memory responses against common viral pathogens such as CMV and EBV unfold superior anti-tumor activity compared to conventional memory responses under APEC therapy in an ICB-resistant preclinical model of HNSCC. Mechanistically, APEC activation required cancer cell-intrinsic protease activity, even for proteases expressed by cells of the tumor stroma. Data mining and functional screening identified the protease activity of plasminogen activator urokinase (PLAU) as widely shared between human HNSCC cancers and as a highly efficient proteolytic activator of APECs. Furthermore, peripheral blood analysis in HNSCC patients reliably predicts the specificity, magnitude, and quality of intratumoral bystander CTL, thus allowing for the screening of HNSCC patients who may benefit most from APEC therapy.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A reservoir of stem-like CD8 T cells in the tumor-draining lymph node maintains the ongoing anti-tumor immune response 96%
- Cellular selectivity of STING stimulation determines priming of tumor-specific T cell responses 95%
- Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5 95%
Similar papers in this journal
- MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer 97%
- A Mimicry-Based Strategy Between Human and Commensal Antigens for the Development of a New Family of Immune Therapies for Cancer 96%
- Pooled screening for CAR function identifies novel IL13Rα2-targeted CARs for treatment of glioblastoma 96%
Similar papers in this journal
- Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors 95%
- Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals 95%
- Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers 95%
Similar papers in this journal
- Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction 96%
- SARS-CoV2 mRNA-vaccination-induced Immunological Memory in Human Non-Lymphoid and Lymphoid Tissues 95%
- Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer 95%
Similar papers in this journal
- Epstein Barr virus infection induces tissue-resident memory T cells in mucosal lymphoid tissues 96%
- T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components 95%
- Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.